Please assess the completion status of the following clinical trial:

Trial Title: Zalutumumab in Head and Neck Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of squamous cell carcinoma of the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx or larynx.~* Primary or recurrent disease for which no curative or established palliative treatments are amenable~* WHO performance status of 1 or 2.~Exclusion Criteria:~* Received certain other treatments within 4 weeks prior to administration of study drug~* Previous severe allergic reactions (e.g. angio-edema, severe asthma, or anaphylaxis).~* Skin disease requiring systemic or local corticosteroid therapy.~* Known brain metastasis or leptomeningeal disease.~* Signs or symptoms of acute illness.~* Bacterial, fungal or viral infection.~* Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, myocardial infarction within one year and stomach, lung, heart, hormonal, nerve or blood diseases.~* Pregnant or breast-feeding women.~* Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial.~* Simultaneous participation in any other trial involving investigational drugs or having participated in a trial within 4 weeks prior to start of trial treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zalutumumab 0.15 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 0.5 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 1 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 2 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 4 mg/kg (Type: EXPERIMENTAL): None
- Zalutumumab 8 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).